WSE-listed Medicalgorithmics has signed an agreement with a North American deep-tech company specializing in the integration of advanced materials, sensors, and artificial intelligence (AI). The North American partner, a leader in textile computing, recently launched an at-home cardiac monitoring service utilizing AI-powered Holter devices. The agreement covers the use of Medicalgorithmics’ proprietary DRAI software and DRP platform, with a contractual minimum annual revenue of PLN 382.8 thousand.
“Another global innovator has recognized the quality and efficiency of our technology. Signing our 15th agreement this year demonstrates a significant acceleration in our business momentum. Our North American partner, known for AI-driven innovations in smart textiles and wearable devices, brings extensive experience and a robust R&D infrastructure. According to their estimates, they plan a dynamic expansion of cardiac monitoring services, potentially reaching up to 200,000 monitoring sessions per year. Our groundbreaking DRAI algorithms and DRP platform will once again serve as the technological foundation of a major project – one that showcases not only the uniqueness of our solutions, but also the market potential and growth prospects for Medicalgorithmics,” said Dr. Kris Siemionow, CEO of Medicalgorithmics.
The partner is a deep-tech company that has been developing cutting-edge textile computing technologies for over a decade- integrating advanced materials, sensors, and AI into intelligent textiles. Through strategic acquisitions, it has significantly expanded its operational scale and capabilities, from biometric sensors to secure data sharing. The company develops innovative products, including garments with embedded materials for monitoring vital signs. In March this year, it launched a service platform utilizing AI-powered textile Holter devices for at-home cardiac monitoring.
Today’s agreement marks the 15th contract signed by Medicalgorithmics in 2025 – a year characterized by record-breaking interest in its medtech solutions and accelerated customer acquisition and integration. By the end of July, the company had completed integration with 28% of the new clients acquired this year (4 out of 14 at that time). The onboarding of additional clients, including a European IDTF, contributed to a 33% year-over-year revenue increase in July. The client integration and testing phase – which can only begin after signing the contract – typically takes 6–10 months. This means that Medicalgorithmics expects to begin monetizing further agreements signed this year before year-end.